Integra Lifesciences Holdings (IART) Net Cash Flow (2009 - 2026)

Integra Lifesciences Holdings has disclosed Net Cash Flow across 18 years of filings, most recently posting -$21.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 37.11% year-over-year to -$21.3 million; the TTM figure through Jun 2026 stood at -$1.7 million (up 87.83% YoY), while the FY2025 annual figure was -$29.3 million, down 24.53% from the prior year.
• Net Cash Flow came in at -$21.3 million for Q2 2026 at Integra Lifesciences Holdings, down from $3.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $320.5 million in Q1 2024 to a low of -$375.5 million in Q2 2024.
• Average Net Cash Flow over 5 years is -$16.7 million, with a median of -$6.6 million recorded in 2023.
• The largest YoY upside for Net Cash Flow was 832.74% in 2024 against a maximum downside of 18527.13% in 2024.
• Over 5 years, Net Cash Flow stood at -$67.2 million in 2022, then surged by 92.01% to -$5.4 million in 2023, then surged by 832.74% to $39.3 million in 2024, then tumbled by 96.82% to $1.3 million in 2025, then tumbled by 1802.56% to -$21.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$21.3 million in Q2 2026, $3.3 million in Q1 2026, and $1.3 million in Q4 2025.